Menu
Nano-antibody (Nb), also called single domain antibody (sdAb) or heavy-chain variable (VHH), is are small, stable, and soluble single-domain antibody (~15 kDa) derived from camelid heavy-chain antibodies. Their compact structure enables high affinity, deep tissue penetration, and access to hidden epitopes beyond the reach of conventional antibodies — making them powerful tools in diagnostics and therapeutics, including oncology, infectious diseases, and autoimmune disorders.
Yaohai Bio-Pharma provides an end-to-end nano-body CRDMO platform based on E. coli and yeast, ensuring high-yield, consistent-quality nano-body development from R&D to commercialization.
Yaohai Bio-Pharma delivers tailored solutions for global clients, meeting diverse project requirements with excellence and efficiency.
Proven track record of over 100 successful projects, spanning preclinical studies and Phase I/II/III clinical trials, including US–China dual submissions and Australian regulatory filings.
A robust GMP-aligned quality system with standardized SOPs, fully compliant with global regulatory guidelines across the entire product lifecycle.
Powered by industry-leading scientists and cross-functional experts, our team delivers CRDMO projects with speed, precision, and deep technical insight.
